Related Articles
Public Health Sex Party Hypocrisy | The VPZD Show Ep. 35
Former New York public health official Jay Varma’s hypocritical sex parties during COVID, why we refuse to talk to most reporters, VP’s take on the…
Hospital Denies Transplant Because Woman Didn’t get the COVID Vaccine – A Bad Policy
Vinay Prasad, MD MPH; Physician & Professor Hematologist/ OncologistProfessor of Epidemiology, Biostatistics and MedicineAuthor of 500+ Peer Reviewed papers,…
Reporting of Postprotocol Therapies and Attrition in Multiple Myeloma Randomized Clinical Trials: A Systematic Review
What proportion of multiple myeloma randomized clinical trials report postprotocol therapies, and when reported, how do these therapies compare with existing standard of care?In this…
Frontiers | Multiple myeloma: challenges with deciding the optimal sequencing strategy
The therapeutic landscape for multiple myeloma (MM) has witnessed great advances over the past two decades, with 19 FDA-approved drugs currently available. T…
Oral ixazomib maintenance following autologous stem cell transplantation (TOURMALINE-MM3): a double-blind, randomised, placebo-controlled phase 3 trial
Ixazomib maintenance prolongs PFS and represents an additional option for post-transplant maintenance therapy in patients with newly diagnosed multiple myeloma.
Let’s take a close look at PARADIGM-HF
10 years later here is the original un-redacted debate between Milt Packer and myself
What Questions are Current Myeloma Trials NOT Answering | Invited Talk to UK Myeloma Research Day
A link to our paper that I didn’t mention but should havehttps://ashpublications.org/blood/article/137/4/456/474255/Persistent-challenges-with-treating-multi…
Imatinib remains the best frontline therapy in patients with chronic myeloid leukemia: Critical analysis of the ASC4FIRST trial
Click on the article title to read more.